glp 1 super revolution GLP-1 Drugs: 6 Things We've Learned About Their Effects GLP1 Elevate™ - GLP-1 Booster

Glucagon-like peptide 1 (GLP-1) Mol Metabol

Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

doi: 10.1016/j.diabres.2012.10.017

Compounded drugs can be important for overcoming shortages or meeting unique patient needs but compounders should not try to compound drugs in a way that circumvents FDAs approval process. Non-FDA-Approved GLP-1 Drugs This follows last months announcement that the FDA plans to take decisive steps in restricting non-FDA-approved GLP-1 receptor agonists

They work by mimicking the hormone GLP-1, helping to regulate blood sugar while dramatically reducing appetite

2535% loss rates) 11:05 What efficacy estimate really means (race-track analogy) 13:28 Real-world view: treatment-regimen estimate (2023.7%) vs trial ideal 15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ 18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences) 21:02 Why the lower doses matter & who actually needs 30% weight loss 24:15 From just make the scale go down to quality of weight loss & body composition 28:05 Future focus: health, longevity, and peptides beyond hitting goal weight 30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & talk to your doctor 34:38 How retatrutide changes the next decade of obesity treatment conversations 37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook 40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review 45:20 Why small-molecule oral GLP-1s arent the same as injectable peptides 48:40 New topic: Indiana Safe Drug Act of 2025 and why Dave is concerned 51:02 Production caps, essentially a copy language & shifting power from prescribers to FDA 54:28 How the bill undermines personalization while ignoring real safety tools 57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting 59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors 1:02:05 Call to action: petition at otplinks.com & why patient voices matter 1:05:10 Change.org impact, media attention & centering the patient perspective 1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks Visit Our Sponsors